TALPHERA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.05 USD | -6.25% |
|
+6.06% | +42.86% |
| Mar. 06 | Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024 |
Presentation Operator MessageOperator (Operator)Welcome to the AcelRx Second Quarter 2023 Fina...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.05
USD
Average target price
5.125
USD
Spread / Average Target
+388.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.86% | 17.82M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- TLPH Stock
- News Talphera, Inc.
- Transcript : AcelRx Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023
